ASP1948

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc., Astellas Pharma Inc

Conditions

Advanced Solid TumorsLocally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

Phase 1

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

CompletedNCT03565445

Astellas Pharma Global Development, Inc.Advanced Solid Tumors

Start: 2018-07-02End: 2023-03-27Updated: 2024-11-01

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

CompletedNCT04094506

Astellas Pharma IncLocally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

Start: 2019-10-30End: 2022-02-02Updated: 2024-11-01